P
Pierre Duvillard
Researcher at Institut Gustave Roussy
Publications - 363
Citations - 14200
Pierre Duvillard is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Survival rate & Ovarian tumor. The author has an hindex of 62, co-authored 363 publications receiving 12991 citations. Previous affiliations of Pierre Duvillard include St. Joseph Hospital.
Papers
More filters
Journal ArticleDOI
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
Emmanuel Mitry,Eric Baudin,Michel Ducreux,Jean-Christophe Sabourin,P Rufié,T. Aparicio,P. Lasser,Dominique Elias,Pierre Duvillard,Martin Schlumberger,Ph. Rougier +10 more
TL;DR: It is confirmed that poorly differentiated neuroendocrine tumours are chemosensitive to the etoposide plus cisplatin combination, however, the prognosis remains poor with a 2-year survival lower than 20% confirming that new therapeutic strategies have to be developed.
Journal ArticleDOI
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Stephanie M. de Boer,Melanie E Powell,Linda Mileshkin,Dionyssios Katsaros,Paul Bessette,Christine Haie-Meder,Petronella B. Ottevanger,Jonathan A. Ledermann,Pearly Khaw,Alessandro Colombo,Anthony Fyles,Marie Helene Baron,Ina M. Jürgenliemk-Schulz,Henry C Kitchener,Hans W. Nijman,G. Wilson,Susan Brooks,Silvestro Carinelli,Diane Provencher,Chantal Hanzen,Ludy C.H.W. Lutgens,Vincent T.H.B.M. Smit,Naveena Singh,V. Do,Romerai D'Amico,Remi A. Nout,Amanda Feeney,Karen W Verhoeven-Adema,Hein Putter,Carien L. Creutzberg,Mary McCormack,Karen Whitmarsh,Rozenn Allerton,Deborah Gregory,P. Symonds,Peter Hoskin,Madhavi Adusumalli,Anjana Anand,Robert Wade,Alexandra J. Stewart,Wendy Taylor,Roy F.P.M. Kruitwagen,Harry Hollema,Elizabeth Pras,An Snyers,Lukas J.A. Stalpers,Jan J. Jobsen,Annerie Slot,Jan Willem M. Mens,Tanja C. Stam,Baukelien Van Triest,Elzbieta M. Van der Steen Banasik,Karin A.J. De Winter,Michael A. Quinn,Ilka Kolodziej,Jan Pyman,Carol Johnson,Anne Capp,Roldano Fossati,Sergio Gribaudo,Andrea Lissoni,Annamaria Ferrero,Grazia Artioli,Cathy Davidson,C. Meg McLachlin,Prafull Ghatage,Paula V.C. Rittenberg,Luis Souhami,Gillian Thomas,Pierre Duvillard,Dominique Berton-Rigaud,Nicole Tubiana-Mathieu +71 more
TL;DR: Adjuvant chemotherapy given during and after radiotherapy for high-risk endometrial cancer did not improve 5-year overall survival, although it did increase failure-free survival.
Journal ArticleDOI
Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
Eve Maubec,Peter Petrow,Isabelle Scheer-Senyarich,Pierre Duvillard,Ludovic Lacroix,Julien Gelly,Agnès Certain,Xavier Duval,Béatrice Crickx,Valérie Buffard,Nicole Basset-Seguin,Pierre Saez,Anne-Bénédicte Duval-Modeste,Henri Adamski,Sandrine Mansard,Florent Grange,Anne Dompmartin,Sandrine Faivre,Marie-Françoise Avril +18 more
TL;DR: A randomized phase III trial is warranted to confirm that cetuximab may be considered as a therapeutic option especially in elderly patients, as a first-line treatment in patients with unresectable SCCS.
Journal ArticleDOI
Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging.
Clarisse Dromain,Thierry de Baere,Jean Lumbroso,Hubert Caillet,Agnès Laplanche,Valérie Boige,Michel Ducreux,Pierre Duvillard,Dominique Elias,Martin Schlumberger,Robert Sigal,Eric Baudin +11 more
TL;DR: MRI seems to have an edge over CT and SRS for the detection of liver metastases from endocrine tumors, and the systematic performance of liver MRI at WDGEP ET initial staging and before major therapeutic events is recommended.
Journal Article
Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice.
TL;DR: The epithelial morphology of IGROV1 cells was retained during in vitro and in vivo passages, as judged by both the light and the electron microscopes, which make the cell line a suitable experimental model for the treatment of human ovarian carcinomas and for biological studies of human solid tumors.